Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Double-Dummy Placebo-Controlled Phase 3 Trial of Dimethyl Fumarate vs Peginterferon Beta-1a in RRMS
2018-000516-22Phase 3Withdrawn
- Sponsor
- Biogen
- Start
- Nov 2018
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Dimethyl fumarate, Peginterferon beta-1a and Placebo (3 arms). Primary endpoint: TTFR. Planned start Nov 2018; status: withdrawn.
02
Drugs
dimethyl fumaratepeginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-000516-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000516-22.